Contact
Home • Our expertise • Commercial • Portfolio, Licensing & Development

Portfolio, Licensing & Development.

Build and optimize your product and portfolio value.

See our full suite of Commercial Strategy services

What we do.

Prepare for lasting clinical and commercial success when you build and optimize your product and portfolio value with us. Science-based, future-focused, and comprehensive, our strategies provide sound guidance for your most critical clinical development, opportunity prioritization, and go/no-go decisions.

How we help.

With a unique blend of clinical and scientific expertise, innovative business strategy, and more than three decades of strategic experience, we advise on optimal and sustainable pharmaceutical portfolio analysis and diligence and early pipeline strategies.

Rooted in a strong understanding of the science and evolving market, we can help your cross–functional teams understand where to position their early–stage assets and platforms in the future landscape, and how to optimize their clinical development path and maximize the asset value.

Learn about our Centers of Excellence

We can help you with:

  • Target screening and prioritization
  • Current and emerging disease landscape
  • Opportunity prioritization
  • Clinical development and regulatory strategy
  • Technology and asset scans to support BD&L
  • Due diligence and in–licensing/out–licensing structuring
  • Long–term portfolio strategy, planning, and optimization

Featured case study

Early oncology portfolio execution roadmap.

Our team was tasked with developing a forward-looking early development program evaluation tool within the US market.
View all case studies
Featured

Early oncology portfolio execution roadmap

We developed a forward-looking early development program evaluation tool that identifies key inflection points for early oncology portfolio.

Read more

Get to know some of our experts.

John L’Ecuyer

Executive Director, Business Development

Read bio

Joseph Feingold

Partner, Portfolio, Licensing & Development Practice Lead & Head of Advanced Technologies Center of Excellence

Read bio

Vikram Gosain

Partner

Read bio

Latest thinking.

Get the latest insights and perspectives from our experts.

View all of our resources

Spotlight on antibody drug conjugates (ADCs)

ADCs continued to be a spotlight at ESMO 2023. The team shares its key value drivers and associated limitations.

Read more

New Principal out of London joins Putnam

Putnam is pleased to announce the addition of Stephen McGarry to the team. He started in June 2023 as a Principal out of the firm’s London office.

Read more

Go/no-go decision for early asset

The client sought Putnam’s guidance on a go/no-go development decision for a first-generation targeted therapy in Phase 1 clinical development.

Read more

Portfolio prioritization and optimization

A clinical-stage biopharmaceutical company sought Putnam’s guidance to prioritize asset-level strategies through a holistic review of options.

Read more

Get in touch.

Looking to get in touch with an expert or team member?

Tell us how we can help.

Contact us today

Related offerings.

Commercial

Learn more

Commercialization & Growth

Learn more

Data Strategy, Analytics & AI

Learn more
View all of our areas of expertise